^
Association details:
| Biomarker: | BCR-ABL1 fusion |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) + Blincyto (blinatumomab) (CD3 agonist, CD19 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults
Published date:
10/22/2020
Excerpt:
ABL1 mutations were detected in 6 patients who had increased minimal residual disease during induction therapy....first-line treatment with dasatinib and blinatumomab...
DOI:
10.1056/NEJMoa2016272
Trial ID:
